Biomarkers and Cardiac CT
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Venous blood sampling prior to CCTA..
- Who it may be relevant to
- Registry conditions: Coronary Artery Disease, Atherosclerosis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Netherlands
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Biomarkers and Cardiac Computed Tomography: Relationship Between Cardiovascular Biomarkers and Coronary Artery Disease in Patients Undergoing Cardiac Computed Tomography
Overview
Coronary artery disease (CAD) is the leading cause of morbidity and mortality in developed countries. In addition, many patients suffer from valvular and aortic disease. Although various tools are available to identify patients with cardiovascular (CV) disease at risk for major adverse cardiac events (MACE), the identification of these patients remains a clinical challenge. One promising avenue is the use of different serum biomarkers involved in atherothrombosis which could provide an easy and cost-effective step in risk stratification.
Interventions
- Biological Venous blood sampling prior to CCTA.
Primary outcome measures
- Data registration of patients undergoing CCTA and given written informed consent. [Time frame: 15 years.]
- To detect these patients for cardiovascular disease and Long term CV outcome (MACE). [Time frame: 15 years.]
Secondary outcome measures (3)
- The relationship of novel blood biomarkers with CCTA findings. [Time frame: 15 years.]
- The predictive value of these biomarkers to predict CAD in patients undergoing CCTA. [Time frame: 15 years.]
- The prognostic value of these biomarkers (in combination) to predict MACE. [Time frame: 15 years.]
Eligibility criteria
Inclusion criteria
- Patients referred from the Cardiology clinic for routine CCTA.
Exclusion criteria
- Pregnancy
- Severe renal insufficiency
- Severe allergy to contrast medium
- Inability to obtain informed consent
- Age below 18 years
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Netherlands · 1 center
- Maastricht University Medical Center — Maastricht
Identifiers
NCT: NCT02381301 · METC 14-4-117